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Abstract
Cardiac surgery using cardiopulmonary bypass produces a
generalized systemic inflammatory response, resulting in increased
postoperative morbidity and mortality. Under these circumstances,
a typical pattern of thyroid abnormalities is seen in the absence of
primary disease, defined as sick euthyroid syndrome (SES). The
presence of postoperative SES mainly in small children and
neonates exposed to long bypass times and the pharmacological
profile of thyroid hormones and their effects on the cardiovascular
physiology make supplementation therapy an attractive treatment
option to improve postoperative morbidity and mortality. Many
studies have been performed with conflicting results. In this article,
we review the important literature on the development of SES in
paediatric postoperative cardiac patients, analyse the existing
information on thyroid hormone replacement therapy in this patient
group and try to summarize the findings for a recommendation.
Introduction
During systemic illness, especially after cardiac surgery using
cardiopulmonary bypass (CBP), abnormalities in the
circulating thyroid hormone levels are found in the absence of
primary thyroid disease; this is collectively called the sick
euthyroid syndrome (SES). Some argue that it is unclear if
the clinical picture of SES is an adaptive process, a marker of
the severity of illness or even if treatment is warranted in
these patients.
The many effects of thyroid hormones on the cardiovascular
system have been described in detail elsewhere [1-3]. The
biological actions of thyroid hormones on the cardiovascular
system make these hormones attractive as a potential treatment
option in the management of patients after cardiac surgery.
We review the actual literature on the development of SES in
children after cardiac surgery and discuss the relevant
literature on hormone replacement. Finally, a critical appraisal
of the potential effects of hormone replacement and the
studies performed is sought.
Sick euthyroid syndrome
It is well known that several severe diseases can cause
abnormalities in the circulating thyroid hormone levels in the
absence of primary thyroid disease (i.e., non-thyroidal illness
or SES) [4].
The most common pattern is a decrease in total and unbound
triiodothyronin (T3) with normal levels of thyroid stimulating
hormone (TSH) and thyroxin (T4). This is classified as SES
type 1 (SES-1) or low-T3 syndrome. The de-ionidation from
T4 to T3 via peripheral (hepatic) enzymes (inhibition of 5′-
deionidase, a selenoenzyme [5,6]) is impaired, leading to a
decrease of T3 and an increase in reverse T3 that is
biologically inactive [7]. Inflammatory cytokines have been
linked to the development of SES [8] and the levels of
cytokines seem to influence the severity of SES [9,10].
Elevated serum levels of steroids as part of a stress response
may influence the de-ionidase activity and TSH and T3
response in SES [8,11-13]. Additionally, tissue-specific
thyroid hormone bioactivity is reduced during cellular hypoxia
and contributes to the low T(3) syndrome of severe illness
[14]. In general, the severity of illness is correlated to the
severity of SES [15-17].
Very sick patients may show a dramatic fall in total T3 and T4
levels; this state is called the low-T4 syndrome or SES type 2
(SES-2) and has a poor prognosis [18,19]. T4 metabolism
may further be influenced by a decrease in thyroid binding
globulin levels [20].
In both SES-1 and SES-2, serum levels of TSH are impaired
and do not increase in reaction to low T3 or T4 levels.
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Patients with low or undetectable TSH show increased
morbidity and mortality [15,21,22]. Additionally, the response
of TSH to thyroid releasing hormone (TRH) is impaired in
SES [23].
Prognostic impact of thyroid hormones on
outcome
In addition to the results discussed above, SES does have a
significant impact on outcome and survival. In 1995, Rothwell
and Lawler [24] used thyroid hormone levels to predict
outcome in adult intensive care patients and showed that an
endocrine prognostic index based on intensive care unit
admission measurements of these hormone levels is a
superior discriminator of patient outcome than the APACHE II
score. Similar results were obtained earlier [25], as well as by
Jarek and colleagues in 1993 [26] and Koh and colleagues in
1996 [27] and was confirmed by Chinga-Alayo and
colleagues in 2005 [28]. In their study with 113 patients, the
addition of thyroid hormone levels to the APACHE score
improved the prediction of mortality [28]. Similar results were
reported by Iervasi and colleagues [29], who assessed
prospectively the role of thyroid hormones in the prognosis of
patients with heart disease. In their cohort of 573
consecutive patients, low levels of free T3 were found to be
the highest independent predictor of death, especially in
cardiac patients. Parle and colleagues [30] presented a large
10 year follow-up cohort study of 1,191 patients and were
able to correlate a single measurement of low TSH in
individuals aged 60 years and older with increased mortality
from all causes and in particular mortality due to circulatory
and cardiovascular diseases.
Thus, the degree of SES seems to have significant influence
on a patient’s outcome under various conditions.
Sick euthyroid syndrome in children
Classic SES-1 was found in several studies in children [31-
33], including after bone marrow transplant [34], in meningitis
[35,36], menigococcal disease [37], Hodgkin’s disease [38],
hepatitis [39], metabolic acidosis due to diarrhoea or diabetic
ketoacidosis [40,41] and sepsis [42]. The thyroid function in
neonates and premature babies is impaired and thyroid
function disorders associated with neonatal adaption and
illness are well described [43,44]. Dopamine infusion
additionally induces or aggravates partial hypopituitarism and
SES in critically ill infants and children [45].
In summary, there is significant evidence that SES plays an
important role in children in various conditions; whereas
SES-1 is related to good outcome and mild to moderate
illness, SES-2 is related to severe illness and poor outcome.
Cardiac operations and the systemic
inflammatory response in children
It is well known that cardiac surgery and CBP leads to a
generalized systematic inflammatory response syndrome
(SIRS), resulting in increased postoperative morbidity and
mortality and organ failure [46,47]. Some of the main clinical
features of postoperative SIRS are hemodynamic impairment,
known as low cardiac output syndrome, capillary leak and
fluid retention. SIRS is characterized by increased post-
operative leucocyte counts, leucocyte activation, oxidative
stress and release of cytokines such as tumor necrosis factor
alpha and IL-6 and IL-8.
Various pharmacological techniques are used to modify or
minimize this response, including the use of high dose steroids
[48]. Other techniques applied routinely are hypothermia, the
use of heparin bonded circuits and oxygenators, intraoperative
continuous hemofiltration or conventional ultrafiltration, post-
operative modified ultrafiltration, leucocyte filtration, and the
postoperative use of peritoneal dialysis to remove inflammatory
cytokines and their impact on postoperative fluid balance
[48-50]. Finally, catecholamines (namely dopamine) and other
drugs such as milrinone are used to support the circulation in
low cardiac output syndrome [51].
In summary, CBP induced SIRS combines many risk factors
contributing to the development of SES as outlined above
and has significant impact on the postoperative course in
paediatric patients.
Paediatric sick euthyroid syndrome after
cardiac surgery
Cardiac surgery with or without cardiopulmonary bypass
induces a marked and persistent depression of circulating
thyroid hormones during the postoperative period in both
adults and children [52-57].
Allen and colleagues [58] demonstrated SES in 12
postoperative cardiac children in 1989 regardless of the
procedure complexity. Bartkowski and colleagues [54]
showed that when a larger amount of T3 is removed by
ultrafiltration, patients show a prolonged recovery. Murzi and
colleagues [59] demonstrated in 14 patients a prolonged
decrease in thyroid hormones for five to seven days.
Belgorosky and colleagues [60] demonstrated similar effects
in 20 prepubertal children undergoing cardiac surgery.
Saatvedt and Lindberg [61] demonstrated a significant
inverse correlation between T3 levels 24 and 48 hours
postoperatively and total accumulated IL-6, and also between
the percentage decrease in T3 concentrations and total
accumulated IL-6.
Bettendorf and colleagues [53] showed in 139 patients a
significant decrease in plasma thyroid hormone levels
consistent with SES-2 and low TSH levels. In those patients
with plasma T3 levels less then 0.6 nmol/l (n = 52), the period
of mechanical ventilation and intensive care treatment was
significantly prolonged. Neonates exposed to bypass and
hypothermia uniformly show a pattern of SES-2 [62];
prolonged SES was demonstrated in older patients after aPage 3 of 8
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Fontan procedure [63]. The magnitude of the fall in serum T3
predicts greater therapeutic requirements in the post-
operative period, especially in neonates [64]. Lynch and
colleagues [65] reported five cases of hypothyroidism
possibly secondary to loss of thyroid binding globulin from
prolonged chest tube drainage.
Peak serum levels of IL-6 were linked to the lowest T3 levels
in 16 children after cardiac surgery [66]; the authors of this
study postulated that treatments directed to diminish the rise
in pro-inflammatory cytokines may prove effective in
preventing postoperative SES. Ririe and colleagues [67]
found no significant impact of deep hypothermic cardio-
circulatory arrest on free T4, free T3 and TSH levels in
children at day 1 and 2 after corrective surgery but this did
lead to an increase of TSH while on bypass.
The concentration of plasma selenium in children undergoing
cardiopulmonary bypass decreases significantly, resulting in
diminished deiodinase activity and a subsequent reduction in
the conversion of T4 to T3 [68]. Free T3 and selenium serum
concentrations were correlated to the time spent in intensive
care. Mitchell and colleagues [69] showed a correlation
between low T3 and T4 levels and survival in 10 infants of less
than 5 kg body weight. In the two patients that died in this small
series, no increase in T3 and T4 or TSH was found after a
trough was reached at 48 to 72 hours after surgery. Plumpton
and Haas finally demonstrated that younger children (less than
three months of age) with longer CBP time (greater than
120 minutes) showed prolonged ventilation after CBP and
lower free T3 levels [52] and concluded that thyroid hormone
replacement therapy in this high-risk group is warranted.
In conclusion, all children submitted to cardiac surgery with
or without cardiopulmonary bypass show a persistent pattern
of SES; in many patients, SES-2 with low T3 and T4 levels
and a low TSH status is demonstrated and there is a close
correlation between the age of the patients bypass time,
postoperative morbidity and the degree of SES [58]. The
profound decrease in thyroid hormones is thought to be of
sufficient magnitude to affect cardiac function [70].
Other confounding factors
Dopamine and thyroid function
Dopamine is often used for treatment of low cardiac output
syndrome. Dopamine directly inhibits anterior pituitary
function through inhibitory dopamine receptors, resulting in
diminished TSH release [71]. The intravenous administration
of dopamine in healthy volunteers produced a reduction in
serum prolactin, TSH, luteinizing hormone and follicle
stimulating hormone while stimulating growth hormone
release; TSH showed a sustained inhibition [72]. Additionally,
dopamine lowers both basal and TRH-mediated TSH release
[73]. This effect was even more sustained in patients with
critical illness [74]. The dopamine-induced or aggravated
pituitary dysfunction in critical illness warrants caution with
prolonged infusion of this catecholamine, particularly in early
life [75]. The administration of dopamine was correlated with
the permanent suppression of TSH in children with
meningococcal shock presenting with severe SES-2 [37]. In
newborns, dopamine was found to suppress prolactin,
growth hormone, and thyrotropin secretion consistently, and
in children, dopamine suppressed prolactin and thyrotropin
secretion, and a rebound release started within 20 minutes
after dopamine withdrawal [45].
Thus, dopamine infusion induces or aggravates partial
hypopituitarism and SES in critically ill infants and children.
Iodinated antiseptics in cardiac surgery
Infants may absorb significant quantities of iodine in iodinated
topical antiseptics transcutaneously [76,77]. Premature and
pre-term infants have been shown to absorb iodine when
treated repeatedly with antiseptics such as povidone-iodine
[78-81]; this patient group is specifically susceptible to
iodine-induced hypothyroidism [82], the so called Wolff-
Chiakoff effect [83]. This effect is detectable when compared
with non-iodine skin disinfectant (chlorhexidine) [84].
Children with delayed sternal closure exposed to povidone-
iodine for sternal wound protection display a more profound
thyroid depression in the immediate postoperative period and
significant iodine absorption [85]. In only one study did
irrigation with povidone-iodine solutions for deep sternal
wound infection not cause significant alteration in thyroid
function in children [86].
Amiodarone
Amiodarone is a highly effective antiarrhythmic agent for
supraventricular and ventricular arrhythmias, especially in the
early postoperative setting [87]. The drug is known to affect
thyroid homeostasis [88] by competitive inhibition of 5′-
monodeiodinase, which converts T4 to T3 and reverse T3 to
3,3′-diodothyronine (T2), and also by the direct effects of its
high iodine content (37% by weight) [89]; it is also structurally
similar to the thyroid hormones [90]. The incidence of thyroid
dysfunction in children is well reported [91] and
hypothyroidisms as well as hyperthyroidism are reported with
varying incidence rates, ranging from about 1% up to 24%
[92-96]. The incidence and severity of side effects seem to be
correlated with age and the dose used, with younger patients
exposed to higher doses at increased risk [96,97].
Thus, the use of amiodarone in the early postoperative setting
may contribute to the development of thyroid dysfunction,
including SES.
Thyroid hormone replacement after cardiac
surgery
The rationale of thyroid hormone replacement/
treatment
A vast literature is available on the changes of thyroid
function during non-thyroidal illness or SES in adults. Therapy
Available online http://ccforum.com/content/10/3/213with T3 has been suggested by many authors but is
controversial. In SES-1 and SES-2, additional tissue-specific
mechanisms are involved in the reduced supply of bioactive
thyroid hormone and replacement of T3 can reverse these
findings [98,99].
T3 administration is associated with improved hemo-
dynamics, reduced peripheral vascular resistance, increased
cardiac output and other effects, suggesting the potential
utility of thyroid hormone replacement [100,101]. In patients
after coronary artery bypass graft (CABG) surgery, an inverse
correlation was found between days of post-operative
hospitalisation and the slope of the recovery of T4 to T3
conversion [102].
Recently, Kokkonen and colleagues [103] demonstrated a
strong association between atrial fibrillation and the low-T3
status. T3 replacement was shown to reduce the rate of
arrhythmias and may be cardio-protective [104].
Novitzky and colleagues [105,106] performed two smaller
randomised studies in 1989 using T3 supplementation and
showed a significantly reduced need for conventional
inotropic agents and diuretics as well as improved stroke
volume, cardiac output, reduced systemic and pulmonary
vascular resistances and survival.
Klemperer and colleagues [107] administered T3 in a
randomised placebo controlled study in 142 high-risk
patients undergoing coronary artery bypass surgery; they
showed a significant increase in cardiac output and a
decrease in systemic vascular resistance. Vavouranakis and
colleagues [108] showed that T3 administration lessened the
need for pharmacological vasodilator therapy, but may
increase heart rate. Sirlak and colleagues [109] pre-treated
patients for planned CABG surgery seven days pre-
operatively and found postoperative lower catecholamine
requirements and a better cardiac output.
Finally Mullis-Jansson [110] and colleagues showed in
another similar study that parenteral T3 led to improved
postoperative function, reduced the need for inotropic agents
and mechanical devices, decreased the incidence of
myocardial ischaemia and decreased the incidence of atrial
fibrillation and pacemaker therapy.
Clinical treatment of children with thyroid hormones
after cardiac surgery
Based on the findings after cardiac surgery and the
pharmacological profile of thyroid hormones, it has been
postulated that thyroid hormone replacement in infants may
reduce postoperative morbidity and mortality [55].
The half-life of intravenous T3 in children is approximately
one-third of that reported for adults and can be calculated at
about 7 hours [111]. Thyronin treatment (T3) was used by
Carrel and colleagues in seven children with severe low
cardiac output syndrome in whom conventional treatment had
failed [112]. All children showed metabolic acidosis and
those with pulmonary hypertension received nitric oxide. Two
patients died (one due to intractable right heart failure and
one after cerebral embolism and who received left ventricular
assist device) but the other five showed a continuous
improvement in hemodynamics within the following 48 to
96 hours. Bialkowsky [113] showed a beneficial effect of T3
supplementation after CBP in children, including significant
vasodilatation. Chowdhury and colleagues [114] initially
reported a case series in 1999 of six children with low
postoperative T3 levels. In these children, T3 treatment
decreased the systemic vascular resistance by more than
25%, increased cardiac output by more than 20%, resolved
the existing metabolic acidosis (base excess > 0) and
reverted junctional rhythm to sinus rhythm in 3/3 patients. The
same group later showed in a prospective trial that T3 levels
are more likely to fall in children after cardiac surgery and that
the magnitude of the fall in serum T3 predicts greater
therapeutic requirements in the postoperative period,
especially in neonates [64].
Mackie and colleagues [115] performed a randomised,
double-blind placebo controlled trial of T3 treatment in a
selective group of 42 patients undergoing a Norwood
procedure or a two-ventricle repair of interrupted aortic arch
and ventricular septum defect. In this high risk group of
patients, T3 supplementation proved to be safe and resulted
in a higher systolic blood pressure and a more rapid
achievement of negative fluid balance. Cardiac index was not
significantly improved. Fluid balance, however, is managed in
many centres worldwide by the use of peritoneal dialysis and
so the beneficial effects may be negligible [116].
Portman and colleagues [117] performed a small study with 14
patients and showed that T3 replacement prevented circulating
T3 deficiencies and elevated heart rate without a concomitant
decrease in systemic blood pressure, thus indicating increased
cardiac output. Myocardial oxygen consumption improves with
an elevation of peak systolic pressure and T3 repletion may
thus enhance cardiac function reserve.
Potential side effects of thyroid hormone replacement
The acute application of thyroid hormone may have
unexpected side effects based on the physiological profile of
the hormones. Subclinical thyrotoxicosis may be associated
with changes in cardiac performance and morphology; these
may include increased heart rate, increased left ventricular
mass index, increased cardiac contractility, diastolic dys-
function, and the induction of ectopic atrial beats or
arrhythmias [118].
In adult patients undergoing coronary artery surgery, the intra-
venous infusion of T3 (0.8 µg/kg followed by 0.12 µg/kg/h for
6 hours) did not change hemodynamic variables or inotropic
Critical Care    Vol 10 No 3 Haas et al.
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detected in the incidence of arrhythmia after T3 administra-
tion despite higher postoperative cardiac index and lower
systemic vascular resistance [104,105,107,108,120].
Intravenous T3 (0.4 µg/kg bolus plus 0.1 µg/kg infusion) was
administered over a 6 hour period without side effects in 170
patients undergoing elective coronary artery bypass grafting
and resulted in a lower incidence of pacemaker dependence
(14% versus 25%, P = 0.013) without side effects [110]. The
oral administration of T3 (125 µg/day orally for 7 days pre-
operatively and from the first postoperative day until
discharge) was without side effects in CABG patients [109].
T3 was well tolerated without episodes of ischemia or clinical
arrhythmia in patients with advanced heart failure [121].
Finally, an intravenous bolus of 1 µg/kg T3 followed by
continuous perfusion at 0.06 µg/kg/h was performed without
haemodynamic impairment in 52 consecutive adult cadaveric
organ donors [122].
In pre-term infants less than 28 weeks of gestational age, a
single injection of T3 (0.5 µg/kg) given 22 to 26 hours after
birth only leads to a two day increase of T3 levels and did not
have negative effects on the cardiovascular system [123]. T4
administration reduced vasopressor needs in children with
cessation of neurological function and hemodynamic
instability; no side effects were seen [124].
After a mean bolus dosage of 2 ± 1.5 µg/h of T3, followed by a
continuous infusion of 0.4 ± 0.3 µg/h for a mean duration of
48 ± 12 h, no side effects were demonstrated in a cohort of
adult and paediatric patients suffering from severe low cardiac
output [112]. Again, no side effects were found in 54 adult and
seven paediatric patients suffering from severe low cardiac
output in different clinical conditions with a mean bolus dosage
of 2 ± 1.5 µg/h of T3 followed by a continuous infusion of
0.4 ± 0.3 µg/h for a mean duration of 48 ± 12 h [64,114].
In children, a once daily infusion of T3 (2 µg/kg bodyweight
on day 1 after surgery and 1 µg/kg bodyweight on subsequent
postoperative days up to 12 days after surgery) proved to be
safe without side effects [125]; the cardiac index, however,
improved significantly. The normalization of serum T3 levels in
other studies was reflected in a marked decrease in the
requirement for inotropic support, conversion to normal sinus
rhythm, and progressively improving clinical course without
clinically adverse effects [55,113]. In a cohort of children
undergoing the modified Fontan procedure, the patients
received intravenous T3 at dosages of 0.4, 0.6, and
0.8 µg/kg; no side effects were reported [111]. T3
(0.4 µg/kg) immediately before the start of CBP and again
with myocardial reperfusion led to transient elevation in heart
rate without a concomitant decrease in systemic blood
pressure in infants less than 1 year old undergoing ventricular
septal defect or tetralogy of Fallot repair [117].
When using a continuous infusion of T3 (0.05 µg/kg/h) in
neonates undergoing aortic arch reconstruction, the study
drug was discontinued prematurely in two children because
of hypertension (n = 1) and ectopic atrial tachycardia
(n = 1); heart rate and diastolic blood pressure, however,
were not influenced by T3 supplementation, but systolic
blood pressure was higher in the T3 group (P < 0.001). No
serious adverse events were attributed to T3 administration
[115].
In summary, the administration of T3 to adults and children of
various ages after cardiac surgery as well as in various other
conditions of critical illness proved to be safe and well
tolerated; no side effects have been demonstrated so far.
Conclusion
The modern treatment of children with congenital heart
defects provides worldwide excellent postoperative care with
short ventilation times, short length of stay and low mortality
and morbidity in the majority of clinical circumstances.
Nevertheless, clinically significant SES can be detected,
especially in neonates and children with long bypass times.
At present, existing studies on treating SES in children have
had relatively small subject numbers as well as age and
diagnosis heterogeneity, thereby limiting the ability to
determine significant clinical effects. Thus, to demonstrate a
significant clinical effect of T3 supplementation, large
numbers of patients are needed and the study must include
patients at specific risk for SES and low cardiac output
syndrome [52]. Treatment protocols in these patients,
however, often include in the routine management peritoneal
dialysis, inotropic support and afterload reduction as well as
open chest strategies for a defined number of days; thus,
common outcome parameters such as hours of ventilation,
use of catecholamines, blood pressure, urine output, and so
on may prove difficult to assess [116].
The Triiodothyronine for Infants and Children Undergoing
Cardiopulmonary Bypass (TRICC) study is a multicenter,
randomised, clinical trial designed to determine safety and
efficacy of T3 supplementation in 200 children less than
2 years of age undergoing surgical procedures for congenital
heart disease. Duration of mechanical ventilation after
completion of cardiopulmonary bypass is the primary clinical
outcome parameter and the study also follows multiple
secondary clinical and hemodynamic parameters [126].
Based on the assumptions above, even the results of this
study may fail to establish the routine administration of T3 to
correct SES in children after cardiac surgery.
In summary, children after cardiac surgery are at specific risk
to develop a clinically important SES peri-operatively. Despite
clear evidence from the studies available, the demonstrated
beneficial effects and the clear lack of negative effects make
the prophylactic supplementation of T3 a desirable treatment
option, especially in high-risk groups.
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